Navigation Links
Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
Date:5/21/2013

PROMISE were fatigue (32 percent versus 42 percent), headache (32 percent versus 36 percent) and influenza-like illness (30 percent versus 20 percent), respectively. In addition, rash (19 percent versus 14 percent), itching (24 percent versus 17 percent), neutropenia (15 percent versus 17 percent), anemia (11 percent versus 6 percent), increased bilirubin (6 percent versus 2 percent), and photosensitivity conditions (4 percent versus none) were also observed. One patient in the simeprevir arm and no patients in the placebo arm discontinued treatment due to an adverse event.

Digestive Disease Week® (DDW®) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW takes place May 18 – 21, 2013, at the Orange County Convention Center, Orlando, Florida. The meeting showcases more than 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org.

About PROMISE
PROMISE is a global, Phase 3, randomized, double-blind, placebo-controlled clinical trial assessing the efficacy, safety and tolerability of simeprevir plus pegylated interferon and ribavirin versus pegylated interferon and ribavirin alone in adult patients with genotype 1 chronic hepatitis C with compensated liver disease, including all stages of liver fibrosis, who relapsed after previous interferon-based therapy.

In the PROMISE trial, 393 patients were randomized to receive one 150 mg capsule of simeprevir or placebo once dai
'/>"/>

SOURCE Janssen R&D Ireland
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. PharmacyGPO Buying Group Selects H. D. Smith as Primary National Distributor
2. Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival
3. Healthscope to commercially launch Circadians Cancers of Unknown Primary Diagnostic Test
4. Medical Oncology Association of Southern California Purchasing Network (MPN) Names Cardinal Health Specialty Solutions as its Primary Healthcare Solutions Partner
5. Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint of Clinical Study
6. Jeffrey Modell Foundation Opens Diagnostic Center for Primary Immunodeficiencies at Midwest Immunology Clinic
7. MultiCell Technologies Updates Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer in vitro Models
8. GeneTex, Inc. to Launch a New Primary Antibody against HIF1a
9. Albireo Has Been Granted Orphan Drug Designation for A4250 from the US FDA for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) and for Primary Biliary Cirrhosis (PBC)
10. AcelRx Announces Achievement of the Primary End-Point in Phase 3 Comparative Study Involving the Sufentanil NanoTab PCA System and Plans to Hold a Conference Call and Webcast Tomorrow to Discuss Top-Line Results
11. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)...  Early symptoms of diabetic eye and vision ... technology, coupled with yearly, comprehensive eye exams, are ... of eye diseases, including those associated with diabetes, ... untreated, these diseases can potentially lead to vision ... optometric researchers have deployed a new tool that ...
(Date:10/22/2014)... -- InVivo Therapeutics Holdings Corp. (OTCQB: NVIV) based in ... cord injury (SCI) treatment with their novel Neuro-Spinal Scaffold. ... regrowth in the spinal cord area when cells are ... polymer, the scaffold ultimately breaks down to water and ... NVIV has recently attracted significant investor attention with the ...
(Date:10/22/2014)... YORK , Oct. 22, 2014 Provectus ... dermatology therapies. PV-10, its novel investigational drug for cancer, ... potential for systemic side effects. Its oncology focus is ... Provectus has completed phase 2 trials of PV-10 as ... a topical treatment for atopic dermatitis and psoriasis. ...
Breaking Medicine Technology:Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 2Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 3InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2
... Inc., the largest,privately held spinal implant manufacturer in ... Spacers have been implanted under an,Investigational Device Exemption ... II and Dr. Rhett Murray., The FLEXUS(TM) ... two,spinous processes with minimal disruption to the surrounding ...
... (BiTE) showing clinical benefit in cancer,patients; Blinatumomab enables patients own T ... ... cancer cells, BETHESDA, Md., Aug. 14 Micromet, Inc.,(Nasdaq: ... treatment of cancer, inflammation and autoimmune,diseases, today announced publication of a ...
Cached Medicine Technology:First FLEXUS(TM) Interspinous Spacer Surgeries for IDE Clinical Trial 2Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 2Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 3Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 4Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 5Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 6
(Date:10/22/2014)... -- Two sisters in high school have developed ways ... Medha Krishen use electronic stethoscopes, which electronically amplify body ... patterns or heartbeats. Ilina, a senior at Port ... a way to detect early lung damage in people ... Ilina recorded one breath cycle each from 16 smokers, ...
(Date:10/22/2014)... Salamon HealthDay Reporter TUESDAY, ... conventional in vitro fertilization (IVF) -- the incubation of embryos ... a device inside the vagina, new research suggests. Scientists ... called an INVOcell, might sharply cut costs for pricey IVF ... more accessible to those who don,t live near big-city assisted ...
(Date:10/22/2014)... Thompson HealthDay Reporter , MONDAY, ... Monday officially tightened guidelines for health workers treating Ebola patients, ... use of a respirator at all times. The U.S. ... tougher rules after two Dallas nurses contracted Ebola while caring ... Liberian national Thomas Eric Duncan. Nina Pham is currently being ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 The newly ... must-have source of thousands of facts, figures and forecasts ... and 68 medical sector forecast categories the Worldwide ... global, regional and national views on the worldwide medical ... , The report gives you data for 2010-2019, covering ...
(Date:10/20/2014)... Allegheny General Hospital’s (AGH) Cardiovascular Institute ... to repair a damaged mitral valve as the heart ... developed by Abbott Vascular , is designed to ... condition in which the heart’s mitral valve leaflets fail ... the heart’s left ventricle into the left atrium. The ...
Breaking Medicine News(10 mins):Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3
... THURSDAY, Nov. 24 (HealthDay News) -- Higher doses of ... people suffering from aggressive lymphomas, such as diffuse large ... forms of non-Hodgkin,s lymphoma), according to new research. ... Lancet found this intensive form of chemotherapy, when ...
... , FRIDAY, Nov. 25 (HealthDay News) -- ... the mental health of black adults in the United ... 66 previous studies that included more than 18,000 black ... racism and trauma, including somatization (psychological distress that is ...
... , FRIDAY, Nov. 25 (HealthDay News) -- The sudden return ... cause some people to go into a funk, but an ... of the holidays year-round. "A large part of happiness ... holidays offer punctuated moments of joy we look forward to ...
... should be able to choose where they give birth, concludes ... first-time mums who opt for a home birth are at ... low in all birth settings. The researchers say their ... pregnancies a choice of birth setting" and will enable women ...
... Nov. 23 (HealthDay News) -- A 36-year-old husband and father ... (windpipe) has received the world,s first artificial trachea made with ... in The Lancet described the transplant surgery, which ... Stockholm, Sweden. Without the transplant, the authors of the ...
... HealthDay Reporter , WEDNESDAY, Nov. 23 (HealthDay News) ... enhanced quality of life may have hidden problems that could ... A letter to the editor in the Nov. 24 ... reports severe bleeding complications among trauma patients on the anti-clotting ...
Cached Medicine News:Health News:More Aggressive Chemo May Help Younger Lymphoma Patients: Study 2Health News:More Aggressive Chemo May Help Younger Lymphoma Patients: Study 3Health News:How to Extend Holiday Cheer 2Health News:Pregnant women at low risk of complications can safely be offered a choice of where to give birth 2Health News:1st Artificial Windpipe Made With Stem Cells Seems Successful 2Health News:Newer Blood Thinner May Pose Danger to Trauma Patients 2Health News:Newer Blood Thinner May Pose Danger to Trauma Patients 3
Double-ended. Sharp and blunt 6.5 mm tips. Designated most popular model or size....
Octagonal handle. 3 mm wide....
Desmarres Retractor Size 4...
2.0 mm cup , straight shaft, Flat handle, length 125.0 mm....
Medicine Products: